Comparison of the efficacy of nepafenac 0.1% in quiescent Behçet's uveitis and non-uveitic healthy patients after phacoemulsification surgery.
Mehmed Uğur IşıkNilüfer F YalçındağPublished in: International ophthalmology (2020)
Nepafenac 0.1% has been shown to be effective in suppressing inflammation after cataract surgery in uveitic eyes as well as in healthy eyes. In addition, it has been observed that it does not increase intraocular pressure in both healthy and uveitic eyes and it is safe to use with this regard.
Keyphrases
- cataract surgery
- optical coherence tomography
- end stage renal disease
- newly diagnosed
- ejection fraction
- minimally invasive
- oxidative stress
- signaling pathway
- prognostic factors
- peritoneal dialysis
- coronary artery bypass
- juvenile idiopathic arthritis
- ankylosing spondylitis
- patient reported outcomes
- atrial fibrillation
- rheumatoid arthritis
- coronary artery disease
- surgical site infection